Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven CancersBirgit Wilding, Ralph A. Neumüller|Cancer Discovery|2024Cited by 43